This section of the website is intended for medical professionals only. To access the client page and online store, please click below.
News
Articles
Representatives from the GHC Genetics laboratory attended the prestigious ESHG 2026 conference
We attended the prestigious ESHG 2026 conference, which is one of the leading European events in the field of human and molecular genetics. During the conference, we attended a series of specialized lectures and workshops focused on the latest findings, technologies, and trends in genetic diagnostics. The conference was highly beneficial for us and provided a great deal of inspiration for the further development of our laboratory practices. We were particularly intrigued by the new possibilities of using Trinity technology for the AVITI sequencer, which can significantly streamline and shorten time-consuming sequencing experiments. We also gained new insights into long-read sequencing, which opens up further possibilities for expanding genetic testing.
07. 07. 2026
Cardiology from the Perspective of a Clinical Geneticist
Dr. Veronika Krulišová, M.D., Ph.D., has published a brief overview article in the journal *Acta Medicinae* that highlights the importance of genetics from a cardiological perspective.
The article is attached to this post.
06. 05. 2026
Listen to the podcast for the healthcare journal on predictive genetics
Viktor Furman, CEO of GHC Genetics, and Renáta Michalovská, head of the GHC Genetics laboratory, were guests on the Zdravotnický deník podcast, where they discussed with Tomáš Cikrt what predictive genetics actually offers today, its potential, and its clear limitations. In the podcast, they also addressed topics such as
07. 04. 2026
We are introducing two new screening tests for colon and lung cancer.
GHC Genetics has introduced two new non-invasive screening tests, PulmoScreen and ColonScreen, which can detect serious diseases before they manifest themselves. These are blood screening tests for lung cancer and colorectal cancer. Both tests are based on the so-called analysis of DNA methylation in a blood sample and represent a modern, fast, and highly accessible form of prevention that can detect very early pathological changes in cells that later lead to the development of cancerous growths. By introducing these two screening tests, we are strengthening our position in the field of personalized and predictive medicine. We are putting into practice methods that were only available in research a few years ago. Thanks to them, we can help detect the disease at a stage when treatment is most effective, and patients have the best chance of a full recovery.
03. 12. 2025